Welcome to our dedicated page for Tempus AI SEC filings (Ticker: TEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tempus AI, Inc. (NASDAQ: TEM) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Tempus is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, and its filings offer insight into how it reports financial performance, manages capital, and documents material corporate events.
Investors can review Form 8-K filings where Tempus discloses items such as preliminary financial results, earnings press releases, credit agreement amendments, securities offerings, and other significant developments. For example, Tempus has used 8-K reports to furnish quarterly financial information, describe an automatic shelf registration statement and related prospectus supplement, and detail the terms of its convertible senior notes due 2030, including conversion features, redemption provisions, and associated capped call transactions.
Over time, this page will also surface Tempus’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically include segment information for its Diagnostics and Data and applications businesses, risk factor discussions, and management’s analysis of operations. In addition, users can expect access to ownership and insider transaction disclosures, such as Form 4 filings, when they are available from EDGAR.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings in clear language. Real-time updates from EDGAR help ensure that new TEM filings appear promptly, while AI-generated highlights can draw attention to important terms in credit agreements, securities offerings, or covenant changes. This combination allows readers to navigate Tempus’s regulatory history more efficiently, from capital structure details to ongoing financial reporting.
Schoenherr Thomas Edward reported acquisition or exercise transactions in this Form 4 filing.
Tempus AI, Inc. executive Thomas Edward Schoenherr, CEO of Diagnostics, received an equity award reported as 13,642 shares of Class A Common Stock. This represents two restricted stock unit grants: 3,642 RSUs are fully vested, and 10,000 RSUs will vest in eight equal quarterly installments starting on November 15, 2026. Following this grant, Schoenherr directly holds 108,609 shares of Class A Common Stock. The transaction reflects a compensation-related share award rather than an open-market purchase or sale.
Rogers James William reported acquisition or exercise transactions in this Form 4 filing.
Tempus AI, Inc. reported that its Chief Financial Officer, James William Rogers, received a grant of 10,000 shares of Class A Common Stock in the form of restricted stock units. The award was granted at no cash cost to him and is part of his compensation. The RSUs vest in eight equal quarterly installments beginning on November 15, 2026. Following this grant, he holds 137,248 shares of Class A Common Stock directly.
Polovin Andrew reported acquisition or exercise transactions in this Form 4 filing.
Tempus AI, Inc. reported that EVP and Chief Legal Officer Andrew Polovin received a grant of 10,000 shares of Class A Common Stock in the form of restricted stock units. The RSUs vest in eight equal quarterly installments starting on November 15, 2026. After this award, he directly holds 136,918 shares.
Bartolucci Ryan M reported acquisition or exercise transactions in this Form 4 filing.
Tempus AI, Inc. reported that its Chief Accounting Officer, Ryan M. Bartolucci, received an award of 24,000 shares of Class A Common Stock in the form of restricted stock units. Following this grant, he directly holds 78,157 shares. The RSUs vest in twelve equal quarterly installments beginning on November 15, 2026.
Fukushima Ryan reported acquisition or exercise transactions in this Form 4 filing.
Tempus AI, Inc. executive Ryan Fukushima reported a compensation-related grant of 10,000 shares of Class A Common Stock in the form of restricted stock units. The award was granted at a price of $0 per share and will vest in eight equal quarterly installments starting November 15, 2026.
Following this grant, Fukushima holds 779,347 shares of Class A Common Stock directly, and 148,808 shares are reported as indirectly owned through his spouse. The filing does not show any open-market buying or selling, only the new equity award and an updated indirect holding entry.
Tempus AI, Inc. reported total net revenue of 348,116 (in thousands) for the three months ended March 31, 2026, up from 255,737 (in thousands) a year earlier, driven by growth in both Diagnostics and Data and applications.
Diagnostics revenue reached 261,098 (in thousands), while Data and applications contributed 87,018 (in thousands). Net loss widened to 125,919 (in thousands), compared with 68,037 (in thousands) in the prior-year period, and basic net loss per share was 0.70.
Operating activities used cash of 73,277 (in thousands), but the company ended the quarter with cash, cash equivalents and restricted cash totaling 525,864 (in thousands) and total assets of 2,135,091 (in thousands). Management states that existing cash, cash equivalents and marketable equity securities as of March 31, 2026 will be sufficient to fund the current operating plan for at least one year.
Tempus AI reported strong first-quarter 2026 growth while remaining unprofitable. Revenue rose 36.1% year-over-year to $348.1 million, led by Diagnostics at $261.1 million (34.7% growth) and Data and Applications at $87.0 million (40.5% growth). Gross profit increased 43.1% to $222.0 million, showing improved scale, and non-GAAP loss from operations narrowed to $11.6 million from $25.8 million a year earlier.
The company still posted a larger GAAP net loss of $125.9 million, versus $68.0 million in the prior-year quarter, driven in part by $56.3 million of stock-based compensation and $32.3 million in unrealized losses on marketable securities. Adjusted EBITDA improved to a loss of $2.8 million from a loss of $16.2 million.
Tempus ended the quarter with $643.8 million in cash and marketable securities and guided full-year 2026 revenue up to $1.59–$1.60 billion, about 25% growth, with expected full-year Adjusted EBITDA of roughly $65 million.
Tempus AI, Inc. CEO and Chairman Eric Lefkofsky reported indirect open-market sales of 166,250 shares of Class A Common Stock through entities he manages. The trades were executed under a Rule 10b5-1 trading plan adopted on March 4, 2025.
Blue Media, LLC sold 27,570 shares at a weighted average price of $51.52 and 105,430 shares at $51.03. Gray Media, LLC sold 6,890 shares at a weighted average price of $51.52 and 26,360 shares at $51.03, with individual trade prices ranging from $50.40 to $51.91.
Following these sales, Blue Media, LLC held 15,684,039 shares and Gray Media, LLC held 8,848,673 shares, all reported as indirect holdings. The filing also lists other indirect positions via foundations, LLCs and a 2025 GRAT, plus 2,253,056 shares held directly.
TEM Form 144 filing lists proposed sales of Class A Common shares by named holders. The excerpt shows sales executed on 02/18/2026, 02/19/2026, and 03/26/2026 with transaction examples: 13,587; 133,000; and 33,250 shares. Dollar proceeds are shown for each sale in the excerpt.